Breast Cancer Clinical Trial

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

Summary

This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.

View Full Description

Full Description

This study is being done to study effects of chemotherapy (cancer treatment) on the brain and cognition (thinking). "Chemo-brain" is a term sometimes used to refer to effects of chemotherapy on the brain and cognition (thinking).
This study is being done to test for "chemo-brain" in older adults with breast cancer treated with chemotherapy, and to identify people who are most likely to be affected. The investigators will look at thinking abilities and brain images before and after chemotherapy to see if it can help identify people at risk for cognitive side effects of the treatment, and to better understand effects of treatment on brain structure and function.
The investigators are looking for participants who have either been recently recently diagnosed breast cancer participant or a healthy volunteer.

What is involved in the study:

Memory and Thinking Tests
Imaging: Either MRI/or MRI and PET Scans

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Breast cancer patients treated with chemotherapy- Group 1 (experimental group)

Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +/- imaging components of study
New diagnosis histologically confirmed invasive breast cancer
Treatment plan to include chemotherapy
Female subjects age ≥ 60 years.
Life expectancy ≥ 1 year
Karnofsky Performance Score (KPS) ≥ 80
Ability to understand and the willingness to sign a written informed consent document.

Non-treated breast cancer patient controls- Group 2 (control group)

Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +/- imaging components of study:
New diagnosis histologically confirmed invasive breast cancer
Treatment plan does not include chemotherapy
Age ≥ 60 years.
Life expectancy ≥ 1 year
Karnofsky Performance Score (KPS) ≥ 80
Ability to understand and the willingness to sign a written informed consent document.

Healthy control subjects- Group 3 (control group)

Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +/- imaging components of study:
Age ≥ 60 years.
Life expectancy ≥ 1 year
Karnofsky Performance Score (KPS) ≥ 80
Ability to understand and the willingness to sign a written informed consent document.
Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled Type II diabetes (glucose levels <250) may be included.
Serum Pregnancy Testing: STAT quantitative serum hCG pregnancy testing for all women of childbearing potential. Imaging will not start until and unless the test result returns negative.

Exclusion Criteria:

Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study:

Participants with clinical or radiographic evidence of metastatic CNS disease
Subjects with MMSE scores below 24
Active or history of major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder in mid-life, or treatment with ECT (Mild depression that is well treated with stable dose of SSRI antidepressants may be allowed).
Substance abuse within the past 2 years
Huntington's disease, hydrocephalus or seizure disorder

In addition to exclusion criteria above, participants who exhibit any of the following conditions at screening will not be eligible for admission into imaging portion of the study:

Participants with contraindications to MRI (i.e., implanted metal including pacemakers, cerebral spinal fluid shunts, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in the eyes and those with a history of claustrophobia), injuries to the eyes with metal without X-ray documentation that metal was removed

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT02290834

Recruitment Status:

Recruiting

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Michael Parsons, PhD
Contact
617-643-0282
[email protected]
Michael Parsons, PhD
Principal Investigator
Massachusetts General Hospital/North Shore Cancer Center
Salem Massachusetts, 01970, United States More Info
Therese Mulvey, MD
Contact
678-882-6060
[email protected]
Therese Mulvey, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT02290834

Recruitment Status:

Recruiting

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider